Highlighting Recent Topical Options for Psoriasis, with Linda Stein Gold, MD
In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.
Related Articles
Pivotal Tildrakizumab Trials Meet Endpoint for Psoriatic Arthritis
New phase 3 trials reveal tildrakizumab 100mg significantly improves symptoms in active psoriatic arthritis, offering hope for effective treatment options.
Dermatology Education Foundation DERM NP/PA CME Conference
Coverage of the Dermatology Education Foundation’s DERM NP/PA CME Conference.
HCPLive – Clinical news for connected physicians
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
SURPASS-CVOT: Tirzepatide Bests Dulaglutide for Cardiovascular Protection
Tirzepatide was non-inferior to dulaglutide with an 8% lower rate of MACE-3 events while delivering greater reductions in A1C and weight.
VERONA Meets Primary Endpoint of Time to Supplement in DME, with Yasha Modi, MD
EYP-1901 successfully achieved an extended time to first supplemental treatment versus aflibercept, indicating a potential for further dose interval extension.
AREDS Micronutrients Show No Benefit in Geographic Atrophy, with Paul Hahn, MD, PhD
Hahn discusses his recent study evaluating AREDS’s potential for nonsubfoveal GA regression in response to a recent post hoc analysis.
Faricimab Superior to Aflibercept in Disease Control in Diabetic Macular Edema
A recent analysis of data from the phase 3 YOSEMITE/RHINE trials has indicated a greater reduction in hard exudates using faricimab versus aflibercept.
Patients with Atopic Dermatitis See Treatment-Free Disease Control with Tralokinumab Use
These data were presented at DERM 2025, highlighting recent findings on the impact of tralokinumab on atopic dermatitis.
Aflibercept 8 mg Maintains Long-Term Visual Improvement in Diabetic Macular Edema
Results from an extension study of the PHOTON trial indicate longer-lasting visual and anatomic improvements in patients receiving aflibercept 8mg versus 2mg.
Study Develops and Validates Handheld Device to Screen for Macular Degeneration
Patient responses indicate that the device is simple and easy to use, and clinical data reflects its effectiveness in recognizing hallmark signals of AMD.